Loading clinical trials...
Loading clinical trials...
A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor
The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Phoenix, Arizona, United States
Tucson, Arizona, United States
Costa Mesa, California, United States
Fresno, California, United States
La Jolla, California, United States
Orange, California, United States
Delray Beach, Florida, United States
Fort Lauderdale, Florida, United States
Fort Myers, Florida, United States
Hallandale, Florida, United States
Start Date
March 1, 2006
Primary Completion Date
June 1, 2008
Completion Date
June 1, 2008
Last Updated
July 7, 2020
250
ACTUAL participants
lecozotan SR (SRA-333)
DRUG
Lead Sponsor
Pfizer
NCT07178210
NCT04123314
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions